Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) Stock Price Up 0.2% – Here’s What Happened

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC)’s share price rose 0.2% on Friday. The stock traded as high as $10.71 and last traded at $10.67. Approximately 22,244 shares traded hands during mid-day trading, a decline of 58% from the average session volume of 53,227 shares. The stock had previously closed at $10.65.

Wall Street Analyst Weigh In

Separately, Weiss Ratings raised shares of Oaktree Acquisition Corp. III Life Sciences from a “sell (d+)” rating to a “hold (c-)” rating in a report on Friday, October 2nd. One investment analyst has rated the stock with a Hold rating. According to MarketBeat.com, Oaktree Acquisition Corp. III Life Sciences has a consensus rating of “Hold”.

Oaktree Acquisition Corp. III Life Sciences Stock Performance

The business’s 50-day simple moving average is $10.77 and its 200 day simple moving average is $10.72.

Oaktree Acquisition Corp. III Life Sciences (NASDAQ:OACC) last posted its quarterly earnings results on Wednesday, August 12th. The company reported $0.07 earnings per share (EPS) for the quarter.

Institutional Investors Weigh In On Oaktree Acquisition Corp. III Life Sciences

Hedge funds and other institutional investors have recently made changes to their positions in the business. Lineage Point Capital LP bought a new stake in shares of Oaktree Acquisition Corp. III Life Sciences in the fourth quarter valued at about $2,461,000. Empyrean Capital Partners LP boosted its stake in Oaktree Acquisition Corp. III Life Sciences by 20.0% in the fourth quarter. Empyrean Capital Partners LP now owns 900,000 shares of the company’s stock worth $9,522,000 after purchasing an additional 150,000 shares in the last quarter. Rangeley Capital LLC lifted its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 52.8% during the first quarter. Rangeley Capital LLC now owns 61,188 shares of the company’s stock valued at $647,000 after acquiring an additional 21,156 shares during the period. Finally, DLD Asset Management LP raised its stake in shares of Oaktree Acquisition Corp. III Life Sciences by 0.9% during the first quarter. DLD Asset Management LP now owns 136,735 shares of the company’s stock worth $1,447,000 after buying an additional 1,200 shares during the last quarter.

About Oaktree Acquisition Corp. III Life Sciences

Oaktree Acquisition Corp. III Life Sciences (NASDAQ: OACC) is a special purpose acquisition company (SPAC) formed to identify and complete a business combination with a company in the life sciences sector.

The company does not operate as a traditional commercial business and does not manufacture or sell products or provide healthcare services. Instead, its activities are focused on evaluating potential merger, acquisition, or other business combination opportunities involving businesses such as biotechnology, pharmaceuticals, medical devices, diagnostics, and related healthcare industries.

Oaktree Acquisition Corp.